Literature DB >> 20098337

Oxidative stress and neurobehavioral problems in pediatric acute lymphoblastic leukemia patients undergoing chemotherapy.

Stephanie L Stenzel1, Kevin R Krull, Marilyn Hockenberry, Neelam Jain, Kris Kaemingk, Petra Miketova, Ida M Moore.   

Abstract

Neurobehavioral problems after chemotherapy treatment for pediatric acute lymphoblastic leukemia (ALL) have been a recent focus of investigation. This study extended previous research that suggested oxidative stress as a potential mechanism for chemotherapy-induced central nervous system injury by examining early markers of oxidative stress in relation to subsequent neurobehavioral problems. Oxidized and unoxidized components of phosphatidylcholine (PC) were measured in the cerebrospinal fluid of 87 children with ALL at diagnosis, induction, and consolidation. Behavioral assessments were conducted postconsolidation and at the end of chemotherapy. Results revealed a significant association between physiologic reactivity (high vs. low PC changes from diagnosis) and behavioral outcomes (high vs. low pathology). Elevated oxidized PC fraction change was predictive of increased problems with aggression at the end of therapy as well as postconsolidation adaptability. Furthermore, symptoms of hyperactivity systematically changed over time in relation to both unoxidized PC and oxidized PC fraction reactivity. These findings suggest that symptoms of behavioral problems occur early in the course of chemotherapy and that increases in the cerebrospinal fluid PC markers of oxidative stress during induction and consolidation may help to predict certain future behavioral problems.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20098337      PMCID: PMC3392027          DOI: 10.1097/MPH.0b013e3181c9af84

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  32 in total

1.  Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study.

Authors:  K A Espy; I M Moore; P M Kaufmann; J H Kramer; K Matthay; J J Hutter
Journal:  J Pediatr Psychol       Date:  2001 Jan-Feb

2.  Cognitive consequences and central nervous system injury following treatment for childhood leukemia.

Authors:  I M Moore; K A Espy; P Kaufmann; J Kramer; K Kaemingk; P Miketova; N Mollova; M Kaspar; A Pasvogel; K Schram; W Wara; J Hutter; K Matthay
Journal:  Semin Oncol Nurs       Date:  2000-11       Impact factor: 2.315

Review 3.  Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors.

Authors:  Kevin C Oeffinger; Melissa M Hudson
Journal:  CA Cancer J Clin       Date:  2004 Jul-Aug       Impact factor: 508.702

4.  Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: effect of treatment intensity.

Authors:  Annemieke I Buizer; Leo M J de Sonneville; Marry M van den Heuvel-Eibrink; Anjo J P Veerman
Journal:  Pediatr Blood Cancer       Date:  2005-09       Impact factor: 3.167

5.  Oxidized phospholipids, linked to apolipoprotein B of oxidized LDL, are ligands for macrophage scavenger receptors.

Authors:  K L Gillotte; S Hörkkö; J L Witztum; D Steinberg
Journal:  J Lipid Res       Date:  2000-05       Impact factor: 5.922

6.  Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats.

Authors:  Nermina Jahovic; Hülya Cevik; A Ozer Sehirli; Berrak C Yeğen; Göksel Sener
Journal:  J Pineal Res       Date:  2003-05       Impact factor: 13.007

7.  Late effects in survivors of infant leukemia.

Authors:  W Leung; M Hudson; Y Zhu; G K Rivera; R C Ribeiro; J T Sandlund; L C Bowman; W E Evans; L Kun; C H Pui
Journal:  Leukemia       Date:  2000-07       Impact factor: 11.528

8.  White matter changes on MRI during treatment in children with acute lymphoblastic leukemia: correlation with neuropsychological findings.

Authors:  E Pääkkö; A Harila-Saari; L Vanionpää; S Himanen; J Pyhtinen; M Lanning
Journal:  Med Pediatr Oncol       Date:  2000-11

9.  Childhood cancer survival in Europe and the United States.

Authors:  Gemma Gatta; Riccardo Capocaccia; Michel P Coleman; Lynn A Gloeckler Ries; Franco Berrino
Journal:  Cancer       Date:  2002-10-15       Impact factor: 6.860

10.  Intellectual outcome in children and adolescents with acute lymphoblastic leukaemia treated with chemotherapy alone: age- and sex-related differences.

Authors:  N von der Weid; I Mosimann; A Hirt; P Wacker; M Nenadov Beck; P Imbach; U Caflisch; F Niggli; A Feldges; H P Wagner
Journal:  Eur J Cancer       Date:  2003-02       Impact factor: 9.162

View more
  14 in total

1.  Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review.

Authors:  Yin Ting Cheung; Kevin R Krull
Journal:  Neurosci Biobehav Rev       Date:  2015-04-07       Impact factor: 8.989

2.  Evaluation of Biomarkers of Oxidative Stress and Apoptosis in Patients With Severe Methotrexate Neurotoxicity: A Case Series.

Authors:  Olga A Taylor; Marilyn J Hockenberry; Kathy McCarthy; Patricia Gundy; David Montgomery; Adam Ross; Michael E Scheurer; Ida M Moore
Journal:  J Pediatr Oncol Nurs       Date:  2015-01-30       Impact factor: 1.636

3.  F2-isoprostanes: a measure of oxidative stress in children receiving treatment for leukemia.

Authors:  Marilyn J Hockenberry; Olga A Taylor; Patricia M Gundy; Adam K Ross; Alice Pasvogel; David Montgomery; Phillip Ribbeck; Kathy McCarthy; Ida Moore
Journal:  Biol Res Nurs       Date:  2013-08-15       Impact factor: 2.522

4.  Investigating the relationship between COMT polymorphisms and working memory performance among childhood brain tumor survivors.

Authors:  Robyn A Howarth; Amanda M Adamson; Jason M Ashford; Thomas E Merchant; Robert J Ogg; Stefan E Schulenberg; Susan Ogg; Jiang Li; Shengjie Wu; Xiaoping Xiong; Heather M Conklin
Journal:  Pediatr Blood Cancer       Date:  2013-08-19       Impact factor: 3.167

5.  Influence of Inflammatory and Oxidative Stress Pathways on Longitudinal Symptom Experiences in Children With Leukemia.

Authors:  Marilyn J Hockenberry; Wei Pan; Michael E Scheurer; Mary C Hooke; Olga Taylor; Kari Koerner; David Montgomery; Susan Whitman; Pauline Mitby; Ida Moore
Journal:  Biol Res Nurs       Date:  2019-07-17       Impact factor: 2.522

Review 6.  Children's Oncology Group's 2013 blueprint for research: nursing discipline.

Authors:  Wendy Landier; Marcia Leonard; Kathleen S Ruccione
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

7.  The influence of oxidative stress on symptom occurrence, severity, and distress during childhood leukemia treatment.

Authors:  Marilyn J Hockenberry; Olga A Taylor; Alice Pasvogel; Cheryl Rodgers; Kathy McCarthy; Patricia Gundy; David W Montgomery; Phillip Ribbeck; Michael E Scheurer; Ida M Ki Moore
Journal:  Oncol Nurs Forum       Date:  2014-07-01       Impact factor: 2.172

Review 8.  Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors.

Authors:  Sharon M Castellino; Nicole J Ullrich; Megan J Whelen; Beverly J Lange
Journal:  J Natl Cancer Inst       Date:  2014-07-30       Impact factor: 13.506

9.  Oxidative Stress, Motor Abilities, and Behavioral Adjustment in Children Treated for Acute Lymphoblastic Leukemia.

Authors:  Marilyn J Hockenberry; Kevin R Krull; Kathleen C Insel; Lynnette L Harris; Patricia M Gundy; Kristin B Adkins; Alice E Pasvogel; Olga A Taylor; Kari M Koerner; David W Montgomery; Adam K Ross; Adam Hill; Ida M Moore
Journal:  Oncol Nurs Forum       Date:  2015-09       Impact factor: 2.172

10.  Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study.

Authors:  Alicia S Kunin-Batson; Xiaomin Lu; Lyn Balsamo; Kelsey Graber; Meenakshi Devidas; Stephen P Hunger; William L Carroll; Naomi J Winick; Leonard A Mattano; Kelly W Maloney; Nina S Kadan-Lottick
Journal:  Cancer       Date:  2016-03-29       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.